Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer

M. K. Mohamed, S. Ramalingam, Y. Lin, W. Gooding, C. P. Belani

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Abstract

Background: Gefitinib (Iressa®) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. Patients and methods: Patients (n = 199) with advanced NSCLC were treated with gefitinib (250mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%. Results: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95% CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P<0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival. Conclusions: Occurence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.

Original languageEnglish (US)
Pages (from-to)780-785
Number of pages6
JournalAnnals of Oncology
Volume16
Issue number5
DOIs
StatePublished - May 2005

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this